Sarcosine in ME/CFS

In ME/CFS (ME/CFS, CFS), published studies report lower levels of Sarcosine, also described as Methylglycine, than in healthy controls; long COVID overlap. Clinically, it has been associated with brain fog, depression. This entry summarises Saito et al. 2024. Group-level associations like this do not translate into an individual diagnostic cut-off.

↓ ReducedMetabolic

Summary

Direction in ME/CFS↓ Reduced — lower than in the comparison group
CategoryMetabolic
Also described asMethylglycine
Compared againstHC — LC overlap (healthy controls; long COVID overlap)
Associated symptomsBrain fog, depression
Test typeBlood test (serum / plasma / whole blood)
SourceSaito et al. 2024 — doi:10.3389/fimmu.2024.1341843
Condition atlasME/CFS Biomarker Atlas

Other conditions where Sarcosine is reported

See the cross-condition hub: Sarcosine across conditions.

Trials, interventions and tests

Also sold as a nutrient or supplement

Sarcosine (amino acid). Amino acid supplement. This tag means the analyte is also available orally; it is not a product endorsement and a low or high level does not by itself justify supplementation.

Related Metabolic markers in ME/CFS

Full list: ME/CFS Biomarker Atlas.

Frequently asked questions

Is Sarcosine high or low in ME/CFS?

Reduced. Studies summarised in the OSMF atlas report lower Sarcosine in ME/CFS than in healthy controls; long COVID overlap. Source: Saito et al. 2024.

What symptoms is Sarcosine associated with in ME/CFS?

The cited literature associates this marker with Brain fog, depression. These are population-level associations and do not mean the marker causes the symptoms.

Which test measures Sarcosine?

It is measured as a blood test (serum / plasma / whole blood). Many of the cited studies used research-grade assays, so clinical availability may vary.

Is one abnormal Sarcosine result diagnostic of ME/CFS?

No. No single biomarker is diagnostic of ME/CFS. Sarcosine findings come from group comparisons, overlap considerably between patients and controls, and vary with study design, timing and comparison group. A result should be interpreted by a clinician alongside symptoms, history and other tests.

Is Sarcosine specific to ME/CFS?

No. The same marker is also reported in Long COVID in this atlas, so it reflects shared biology (for example inflammation or vascular stress) rather than a condition-specific signature.

Cite this page

Open Source Medicine Foundation. (2026). Sarcosine in ME/CFS: direction, evidence and what it means. OSMF Research Tracker. Retrieved October 7, 2026, from https://research.opensourcemed.info/biomarkers/me-cfs/sarcosine.html
Get OSMF research updates. New biomarker, trial and treatment evidence summaries by email.
Subscribe on Substack

Last reviewed: 2026-06-29 · Page generated from me-cfs.json · Browse: ME/CFS atlas · Biomarker Index · All marker pages

Disclaimer: This page is an educational synthesis of published, peer-reviewed research and is not medical advice. Biomarker findings vary across studies with case definitions, comparison groups, timing and assay methods. Direction of change reflects the predominant finding in the cited source and does not establish a diagnostic threshold. Discuss any test result with a qualified clinician.